Novel agents induction therapy followed with or without autologous stem cell transplantation in youn

来源 :The 35th World Congress of the International Society of Hema | 被引量 : 0次 | 上传用户:banban0802
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Objective To define the role of autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM) in the era of novel agents,we analyzed the follow-up data in patients treated with novel agents either alone or followed by ASCT.
其他文献
Objective The International Staging System (ISS) is an important prognostic indicator for outcome of patients with multiple myeloma (MM).ISS was proposed in 2005 using data from 10,750 MM patients who
会议
Objective Novel agents-based anti-myeloma regimens including thalidomide and bortezomib have significantly improved myeloma treatment.However,it remains unclear whether patients will benefit more from
会议
Objective High altitude polycythemia (HAPC) is characterized by excessive erythrocytes and enhanced angiogenesis,which is caused by environmental factors such as hypoxia and cold at high altitude.Howe
会议
Introduction Cytogenetic abnormality plays an important role in prognosis of patients with multiple myeloma (MM).Conventional cytogenetic assay reveals limited results.In this study,we performed inter
会议
Background Multiple myeloma (MM) is a plasma-cell malignancy manifested accumulation of abnormal plasma cells in the bone marrow.The purpose of this study is to evaluate the prognosis in patients with
会议
Purpose Global change in protein turnover (protein degradome) constitutes a central part of cellular responses to intrinsic or extrinsic stimuli.However,profiling protein degradome remains technically
会议
Tumor initiating cells play important roles in multiple myeloma (MM) progression,relapse,recurrence,and are critical target for therapy.However,quite few agents have been shown to target tumor initiat
会议
Objective The aim of this meta-analysis of data from phase Ⅲ studies is to characterize efficacy and safety of bortezomib-based versus nonbortezomib-based post-transplantation therapy in patients with
会议
The PAD regime,composed of bortezomib,adriamycin and dexamethasone,improves the outcomes of patients with advanced multiple myeloma (MM),but at the same time produces high frequency of serious toxic s
会议
Heat shock protein 90 (HSP90) is one of the most active molecular chaperones in cell,participating in cellular stress response as well as client protein maturation and stabilization.Cdc37 (cell divisi
会议